Claims
- 1. A compound having the formula (4): wherein R1 and R2 are independently selected from the group hydrogen and a lower alkyl group having one to six carbons; Z is selected from the group consisting of NH, —C—C—, and —C═C—; Z1 is selected from the group consisting of zero, O, NH, CH2, and C═O; Z2 is selected from the group consisting of O or CH2; R5 is selected from the group consisting of H, an alkyl group having one to three carbons, a halogen selected from fluorine, chlorine, bromine and iodine, an alkoxy group having one to three carbons, and OSO2 NR1 R2 wherein R1 and R2 are as described above; m is 0 to 3; and R6 and R7 are independently selected from the group consisting of hydrogen and a lower alkyl group having 1 to 3 carbons or R6 and R7 together form a cyclic structure having the formula —(CH2)q—wherein q is 3 to 6.
- 2. The compound of claim 1 wherein R1 and R2 are both H, Z is —C—C—, Z1 is zero, Z2 is CH2 and n is O.
- 3. The compound of claim 2 wherein R5 is H, R6 is CH3, and R7 is CH3.
- 4. The compound of claim 2 wherein R5 is CH3, R6 is CH3 and R7 is CH3.
- 5. The compound of claim 2 wherein R5 is OCH3, R6 is CH3, and R7 is CH3.
- 6. The compound of claim 2 wherein R5 is OH, R6 is CH3 and R7 is CH3.
- 7. The compound of claim 2 wherein R5 is H and R6 and R7 are together —(CH2)4—.
- 8. The compound of claim 2 wherein R5 is CH3 and R6 and R7 are together —(CH2)4—.
- 9. The compound of claim 2 wherein R5 is OCH3 and R6 and R7 are together —(CH2)4—.
- 10. The compound of claim 2 wherein R5 is OH and R6 and R7 are together —(CH2)4—.
- 11. A method for treating a patient having an estrogen dependent illness comprising administering to said patient an effective amount of a compound having the following formula (4): wherein R1 and R2 are independently selected from the group hydrogen and a lower alkyl group having one to six carbons; Z is selected from the group consisting of NH, —C—C—, and —C═C—; Z1 is selected from the group consisting of zero, O, NH, CH2, and C═O; Z2 is selected from the group consisting of O or CH2; R5 is selected from the group consisting of H, an alkyl group having one to three carbons, a halogen selected from fluorine, chlorine, bromine and iodine, an alkoxy group having one to three carbons, and OSO2 NR1 R2 wherein R1 and R2 are as described above; m is 0 to 3; and R6 and R7 are independently selected from the group consisting of hydrogen and a lower alkyl group having 1 to 3 carbons or R6 and R7 together form a cyclic structure having the formula —(CH2)q- wherein q is 3 to 6.
- 12. The method of claim 11, wherein said compound is incorporated into a suitable pharmaceutical carrier.
- 13. The method of claim 12, wherein said suitably pharmaceutical carrier is physiologic saline, 5 percent dextrose.
- 14. The method of claim 11, wherein said treatment is selected from therapeutic treatment and prophylactic treatment.
- 15. The method of claim 11, wherein said administration is parenteral.
- 16. The method of claim 11, wherein said administration is oral.
- 17. The method of claim 11, wherein R1 and R2 are both H, Z is —C—C—, Z1 is zero, Z2 is CH2 and n is O.
- 18. The method of claim 17, wherein R6 and R7 are both CH3 and R5 is selected from the group H, CH3, OCH3 and OH.
- 19. The method of claim 17, wherein R6 and R7 are together —(CH2)4— and R5 is selected from the group H, CH3, OCH3 and OH.
CROSS REFERENCE TO RELATED APPLICATION
This application is a divisional application of U.S. application Ser. No. 09/536,331, filed Mar. 24, 2000 now U.S. Pat. No. 6,288,107, which is a continuation-in-part of U.S. application Ser. No. 09/164,889, filed Oct. 1, 1998 now U.S. Pat. No. 6,248,780, for “Compounds for the Treatment of Estrogen-Dependent Illnesses and Methods for Making and Using the Same”, the contents of which are hereby incorporated by reference.
US Referenced Citations (10)
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/164889 |
Oct 1998 |
US |
Child |
09/536331 |
|
US |